Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs
(1998) In The International Journal of Tuberculosis and Lung Disease 2(7). p.580-584- Abstract
- SETTING: Addis Ababa Tuberculosis Demonstration and Training Center, Ethiopia. OBJECTIVES: To determine the pattern of drug resistance among re-treatment cases of pulmonary tuberculosis (TB), to determine the risk factors associated with multi-drug resistant (MDR) TB, and to propose re-treatment regimens based on the patterns of susceptibility to first-line and alternative drugs. DESIGN: One hundred and seven Mycobacterium tuberculosis strains isolated from an equal number of re-treatment cases of pulmonary TB were included in the study. Drug susceptibility was determined by the Bactec method. RESULTS: About 50% of the strains were resistant to one or more of the first-line drugs and 12% of the strains were multi-drug resistant, i.e.,... (More)
- SETTING: Addis Ababa Tuberculosis Demonstration and Training Center, Ethiopia. OBJECTIVES: To determine the pattern of drug resistance among re-treatment cases of pulmonary tuberculosis (TB), to determine the risk factors associated with multi-drug resistant (MDR) TB, and to propose re-treatment regimens based on the patterns of susceptibility to first-line and alternative drugs. DESIGN: One hundred and seven Mycobacterium tuberculosis strains isolated from an equal number of re-treatment cases of pulmonary TB were included in the study. Drug susceptibility was determined by the Bactec method. RESULTS: About 50% of the strains were resistant to one or more of the first-line drugs and 12% of the strains were multi-drug resistant, i.e., resistant to both isoniazid and rifampicin. Previous treatment with rifampicin was the most important predictor of MDR-TB. All MDR strains were susceptible to amikacin, ciprofloxacin, ethambutol, ethionamide and clofazimine. CONCLUSION: The WHO re-treatment regimen would theoretically be effective for the treatment of all non-MDR-TB patients in this study. A proposed 12-month re-treatment regimen for MDR-TB patients would include a fluoroquinolone in combination with streptomycin, pyrazinamide, isoniazid, ethambutol and clofazimine. There is an urgent need for more research to define safe and inexpensive treatment regimens for MDR-TB patients in low-income countries. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1113222
- author
- Abate, G ; Miörner, Håkan LU ; Ahmed, O and Hoffner, S E
- publishing date
- 1998
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- multidrug resistance, tuberculosis, Ethiopia
- in
- The International Journal of Tuberculosis and Lung Disease
- volume
- 2
- issue
- 7
- pages
- 580 - 584
- publisher
- International Union against Tuberculosis and Lung Disease
- external identifiers
-
- pmid:9661826
- scopus:0031856006
- ISSN
- 1815-7920
- language
- English
- LU publication?
- no
- id
- 28d70a08-7d9d-46ea-b21a-92a76b5c1f8c (old id 1113222)
- date added to LUP
- 2016-04-01 12:29:07
- date last changed
- 2022-01-27 05:43:12
@article{28d70a08-7d9d-46ea-b21a-92a76b5c1f8c, abstract = {{SETTING: Addis Ababa Tuberculosis Demonstration and Training Center, Ethiopia. OBJECTIVES: To determine the pattern of drug resistance among re-treatment cases of pulmonary tuberculosis (TB), to determine the risk factors associated with multi-drug resistant (MDR) TB, and to propose re-treatment regimens based on the patterns of susceptibility to first-line and alternative drugs. DESIGN: One hundred and seven Mycobacterium tuberculosis strains isolated from an equal number of re-treatment cases of pulmonary TB were included in the study. Drug susceptibility was determined by the Bactec method. RESULTS: About 50% of the strains were resistant to one or more of the first-line drugs and 12% of the strains were multi-drug resistant, i.e., resistant to both isoniazid and rifampicin. Previous treatment with rifampicin was the most important predictor of MDR-TB. All MDR strains were susceptible to amikacin, ciprofloxacin, ethambutol, ethionamide and clofazimine. CONCLUSION: The WHO re-treatment regimen would theoretically be effective for the treatment of all non-MDR-TB patients in this study. A proposed 12-month re-treatment regimen for MDR-TB patients would include a fluoroquinolone in combination with streptomycin, pyrazinamide, isoniazid, ethambutol and clofazimine. There is an urgent need for more research to define safe and inexpensive treatment regimens for MDR-TB patients in low-income countries.}}, author = {{Abate, G and Miörner, Håkan and Ahmed, O and Hoffner, S E}}, issn = {{1815-7920}}, keywords = {{multidrug resistance; tuberculosis; Ethiopia}}, language = {{eng}}, number = {{7}}, pages = {{580--584}}, publisher = {{International Union against Tuberculosis and Lung Disease}}, series = {{The International Journal of Tuberculosis and Lung Disease}}, title = {{Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs}}, volume = {{2}}, year = {{1998}}, }